# T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

> **NCT03190967** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer
- Brain Metastasis
- Brain Cancer

## Interventions

- **DRUG:** T-DM1
- **DRUG:** TMZ

## Key facts

- **NCT ID:** NCT03190967
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-18
- **Primary completion:** 2021-06-28
- **Final completion:** 2023-06-13
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The phase II portion was never started as we could no longer get the drug from the manufacturer.
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190967, "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03190967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*